Literature DB >> 21413941

The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection.

T Bruns1, J Peter, S Hagel, A Herrmann, A Stallmach.   

Abstract

Several functional abnormalities in phagocytes from patients with liver cirrhosis contribute to an increased risk of infection. An increased resting respiratory burst has been observed in neutrophils from cirrhotic patients. We investigated whether an infection in cirrhosis affects the respiratory burst capacity of neutrophils and monocytes in response to Escherichia coli. This study included 45 hospitalized patients with liver cirrhosis and clinical signs of infection, 39 patients with liver cirrhosis in the absence of infection and 29 healthy subjects. Respiratory burst, lipopolysaccharide-binding protein (LBP), and immunoglobulin (Ig)G-autoantibodies against oxidized low-density lipoproteins (ab-oxLDL) were measured. The fraction of neutrophils spontaneously producing reactive oxygen species (ROS) was elevated in liver cirrhosis (P < 0·01). The neutrophil resting burst increased with Child-Pugh stage (P = 0·02) and correlated with augmented ROS release in response to opsonized E. coli (P < 0·05). Although LBP was increased in patients with cirrhosis (P < 0·01), higher LBP levels correlated with a lower resting burst in neutrophils (r(s)  = -0·395; P < 0·01). In the presence of infection, the resting burst was unaltered. However, neutrophil ROS release in response to E. coli was reduced markedly (P = 0·01), and it decreased as serum C-reactive protein (CRP) concentration rose (r(s)  = -0·437; P < 0·01), indicating the development of a sepsis-like immune paralysis. A positive correlation between ab-oxLDL and ROS release was observed (P < 0·01). In conclusion, the respiratory burst increases with severity of liver cirrhosis but is restrained by increasing LBP levels. Augmented ROS release in response to E. coli is accompanied by elevated markers of oxidative damage and becomes exhausted in the presence of infection.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21413941      PMCID: PMC3087930          DOI: 10.1111/j.1365-2249.2011.04373.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  55 in total

Review 1.  Phagocytes and oxidative stress.

Authors:  B M Babior
Journal:  Am J Med       Date:  2000-07       Impact factor: 4.965

2.  Neutrophil activation in chronic liver disease.

Authors:  A J Stanley; I R MacGregor; J F Dillon; I A Bouchier; P C Hayes
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-02       Impact factor: 2.566

3.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

4.  Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14.

Authors:  E Hailman; T Vasselon; M Kelley; L A Busse; M C Hu; H S Lichenstein; P A Detmers; S D Wright
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

5.  Granulocyte colony-stimulating factor improves deficient in vitro neutrophil transendothelial migration in patients with advanced liver disease.

Authors:  Carmen Fiuza; Magdalena Salcedo; Gerardo Clemente; Jose M Tellado
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

6.  Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.

Authors:  E Maggi; E Marchesi; V Ravetta; A Martignoni; G Finardi; G Bellomo
Journal:  J Hypertens       Date:  1995-01       Impact factor: 4.844

7.  Human monocytes use Rac1, not Rac2, in the NADPH oxidase complex.

Authors:  Xiaoxian Zhao; Kevin A Carnevale; Martha K Cathcart
Journal:  J Biol Chem       Date:  2003-08-11       Impact factor: 5.157

8.  Ammonia impairs neutrophil phagocytic function in liver disease.

Authors:  Debbie L Shawcross; Gavin A K Wright; Vanessa Stadlbauer; Stephen J Hodges; Nathan A Davies; Caroline Wheeler-Jones; Andrew A Pitsillides; Rajiv Jalan
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

9.  Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites.

Authors:  Agustín Albillos; Antonio de-la-Hera; Melchor Alvarez-Mon
Journal:  Lancet       Date:  2004-05-15       Impact factor: 79.321

10.  Changes in the production of nitric oxide and superoxide by inflammatory cells in liver cirrhosis.

Authors:  E Masini; L Mugnai; M Foschi; G Laffi; P Gentilini; P F Mannaioni
Journal:  Int Arch Allergy Immunol       Date:  1995 May-Jun       Impact factor: 2.749

View more
  18 in total

1.  Persistence of the bacterial pathogen Granulibacter bethesdensis in chronic granulomatous disease monocytes and macrophages lacking a functional NADPH oxidase.

Authors:  Jessica Chu; Helen H Song; Kol A Zarember; Teresa A Mills; John I Gallin
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

2.  Dysfunction of Circulating Polymorphonuclear Leukocytes and Monocytes in Ambulatory Cirrhotics Predicts Patient Outcome.

Authors:  Konstantina Sargenti; Åsa Johansson; Sara Bertilsson; Inger Mattsby-Baltzer; Daniel Klintman; Evangelos Kalaitzakis
Journal:  Dig Dis Sci       Date:  2016-03-24       Impact factor: 3.199

Review 3.  Cirrhosis-associated immune dysfunction.

Authors:  Agustín Albillos; Rosa Martin-Mateos; Schalk Van der Merwe; Reiner Wiest; Rajiv Jalan; Melchor Álvarez-Mon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-26       Impact factor: 46.802

4.  The Clinical Impact of Cirrhosis on the Hospital Outcomes of Patients Admitted With Influenza Infection: Propensity Score Matched Analysis of 2011-2017 US Hospital Data.

Authors:  David U Lee; Gregory H Fan; David J Hastie; Vibhav N Prakasam; Elyse A Addonizio; Ryan R Ahern; Kristen J Seog; Raffi Karagozian
Journal:  J Clin Exp Hepatol       Date:  2021-02-04

Review 5.  Impairment of innate immune responses in cirrhotic patients and treatment by branched-chain amino acids.

Authors:  Ikuo Nakamura
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 6.  Risk factors and outcome of bacterial infections in cirrhosis.

Authors:  Tony Bruns; Henning W Zimmermann; Andreas Stallmach
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 7.  Immune dysfunction in cirrhosis.

Authors:  Nora Sipeki; Peter Antal-Szalmas; Peter L Lakatos; Maria Papp
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

8.  Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study.

Authors:  Anika Vogt; Philipp A Reuken; Sven Stengel; Andreas Stallmach; Tony Bruns
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

Review 9.  Inflammatory status in human hepatic cirrhosis.

Authors:  María Martínez-Esparza; María Tristán-Manzano; Antonio J Ruiz-Alcaraz; Pilar García-Peñarrubia
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

10.  Attenuated antigen-specific T cell responses in cirrhosis are accompanied by elevated serum interleukin-10 levels and down-regulation of HLA-DR on monocytes.

Authors:  Jack Peter; Oliver Frey; Andreas Stallmach; Tony Bruns
Journal:  BMC Gastroenterol       Date:  2013-02-27       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.